What is Seres Therapeutics Inc's earnings per share (EPS)?

Seres Therapeutics Inc (MCRB) reported diluted earnings per share of $0.64 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Seres Therapeutics Inc Financials

MCRB

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Seres Therapeutics Inc (MCRB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MCRB FY2025 2026-05-05

FY2025 looks like a cost-reset and balance-sheet repair year, while the underlying business still operates with minimal revenue.

Positive net income in FY2025 at $5.7M alongside revenue of just $789K means the reported profit did not come from normal selling activity. With operating loss still at -$94.0M even as free cash flow edged up to $865K, the year reads as a reset of the cost base and capital position rather than evidence that the core business has reached commercial scale.

Liquidity improved materially: cash increased to $45.8M from $30.8M, and the current ratio moved back above 1 to 2.6x. That matters because FY2024 had slipped below near-term self-coverage, while FY2025 shows a balance sheet less dependent on immediate external funding to meet current obligations.

This is still a development-stage operating model, not a scaled commercial one: R&D spending of $49.1M was about 62x FY2025 revenue of $789K. The key operating change over the last two years is lower spending, not higher sales, which is why cash burn improved faster than the operating line.

Financial Health Signals

Financial Profile 39/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Seres Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Seres Therapeutics Inc has an operating margin of -11910.1%, meaning the company retains $-11910 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.

Leverage

Seres Therapeutics Inc has a moderate D/E ratio of 2.13. This balance of debt and equity financing earns a leverage score of 59/100.

Liquidity

Seres Therapeutics Inc's current ratio of 2.56 indicates adequate short-term liquidity, earning a score of 48/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

100

Seres Therapeutics Inc converts 109.6% of revenue into free cash flow ($865K). This strong cash generation earns a score of 100/100.

Returns

Seres Therapeutics Inc's ROE of 12.9% shows moderate profitability relative to equity, earning a score of 30/100. This is up from 1.0% the prior year.

Piotroski F-Score Neutral

5/9

Seres Therapeutics Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.20x

For every $1 of reported earnings, Seres Therapeutics Inc generates $0.20 in operating cash flow ($1.1M OCF vs $5.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$789K

5Y CAGR-52.7%

Seres Therapeutics Inc generated $789K in revenue in fiscal year 2025.

EBITDA

-$89.8M

YoY+22.5%

Seres Therapeutics Inc's EBITDA was -$89.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 22.5% from the prior year.

Net Income

$5.7M

YoY+4088.2%

Seres Therapeutics Inc reported $5.7M in net income in fiscal year 2025. This represents an increase of 4088.2% from the prior year.

EPS (Diluted)

$0.64

Seres Therapeutics Inc earned $0.64 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

$865K

YoY+100.6%

Seres Therapeutics Inc generated $865K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 100.6% from the prior year.

Cash & Debt

$45.8M

YoY+48.6%

5Y CAGR-17.0%

10Y CAGR-4.7%

Seres Therapeutics Inc held $45.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

10M

YoY+10.5%

Seres Therapeutics Inc had 10M shares outstanding in fiscal year 2025. This represents an increase of 10.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-11910.1%

5Y CAGR-11644.8pp

Seres Therapeutics Inc's operating margin was -11910.1% in fiscal year 2025, reflecting core business profitability.

Net Margin

721.9%

5Y CAGR+990.3pp

Seres Therapeutics Inc's net profit margin was 721.9% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

12.9%

YoY+11.9pp

5Y CAGR+63.9pp

10Y CAGR+39.5pp

Seres Therapeutics Inc's ROE was 12.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 11.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$49.1M

YoY-24.1%

5Y CAGR-11.5%

10Y CAGR+2.6%

Seres Therapeutics Inc invested $49.1M in research and development in fiscal year 2025. This represents a decrease of 24.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$252K

YoY-33.7%

5Y CAGR-15.7%

10Y CAGR-24.8%

Seres Therapeutics Inc invested $252K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 33.7% from the prior year.

MCRB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$789K	$0	$0-100.0%	$7.1M-95.1%	$144.9M+336.3%	$33.2M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$49.1M-24.1%	$64.6M-45.1%	$117.6M+7.2%	$109.7M-22.7%	$141.9M+56.7%	$90.6M
SG&A Expenses	$39.2M-26.4%	$53.2M-31.4%	$77.5M+10.3%	$70.3M+1.4%	$69.3M+125.1%	$30.8M
Operating Income	-$94.0M+22.5%	-$121.3M+37.8%	-$195.1M-8.4%	-$179.9M-179.0%	-$64.5M+26.8%	-$88.1M
Interest Expense	$0	$0-100.0%	$2.5M-59.0%	$6.0M+106.9%	$2.9M-0.5%	$2.9M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	$5.7M+4088.2%	$136K+100.1%	-$113.7M+54.5%	-$250.2M-281.5%	-$65.6M+26.4%	-$89.1M
EPS (Diluted)	$0.64	$0.00	$-17.77-669.3%	$-2.31-220.8%	$-0.72+35.7%	$-1.12

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$358K	N/A	$351K	N/A	$0	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$13.2M	N/A	$12.6M-2.5%	$12.9M+9.5%	$11.8M	N/A	$16.5M+4.1%	$15.8M
SG&A Expenses	$8.1M	N/A	$9.5M-7.6%	$10.3M-13.8%	$11.9M	N/A	$12.7M-2.7%	$13.1M
Operating Income	-$20.9M	N/A	-$22.5M+9.7%	-$24.9M+8.6%	-$27.2M	N/A	-$29.2M-1.0%	-$28.9M
Interest Expense	N/A	N/A	N/A	$0	$0	N/A	$0	$0
Income Tax	$0	N/A	$0	$0	$0	N/A	$0	$0
Net Income	-$19.9M	N/A	$8.2M+141.3%	-$19.9M-160.8%	$32.7M	N/A	$88.8M+370.1%	-$32.9M
EPS (Diluted)	$-2.08	N/A	$0.94+141.4%	$-2.27	$3.75	N/A	$11.63+368.0%	$-4.34

MCRB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$138.2M-1.2%	$139.8M-61.0%	$358.6M+2.8%	$348.8M-1.7%	$354.9M+3.5%	$342.9M
Current Assets	$49.4M+27.7%	$38.7M-78.0%	$175.4M-9.9%	$194.8M-35.9%	$303.6M+13.0%	$268.8M
Cash & Equivalents	$45.8M+48.6%	$30.8M-75.9%	$128.0M-21.5%	$163.0M-9.4%	$180.0M+55.1%	$116.0M
Inventory	N/A	N/A	$29.6M	$0	N/A	N/A
Accounts Receivable	$157K	$0	N/A	N/A	N/A	$9.4M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$94.0M-25.4%	$126.0M-68.8%	$403.5M+19.4%	$338.0M+51.3%	$223.4M+32.8%	$168.2M
Current Liabilities	$19.3M-53.1%	$41.2M-58.2%	$98.7M+15.3%	$85.6M+4.1%	$82.3M+77.2%	$46.4M
Long-Term Debt	N/A	N/A	$110.0M+120.0%	$50.0M+107.9%	$24.1M-3.8%	$25.0M
Total Equity	$44.2M+220.8%	$13.8M+130.7%	-$44.9M-516.0%	$10.8M-91.8%	$131.5M-24.7%	$174.8M
Retained Earnings	-$972.4M+0.6%	-$978.1M0.0%	-$978.2M-13.2%	-$864.5M-40.7%	-$614.4M-11.9%	-$548.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$117.6M-14.9%	$138.2M-3.7%	$143.5M-0.2%	$143.8M-12.4%	$164.2M+17.4%	$139.8M-21.8%	$178.7M-44.4%	$321.7M
Current Assets	$31.8M-35.5%	$49.4M-4.2%	$51.5M+5.8%	$48.7M-26.3%	$66.1M+70.9%	$38.7M-47.0%	$72.9M-51.1%	$149.3M
Cash & Equivalents	$29.8M-34.8%	$45.8M-3.9%	$47.6M+5.0%	$45.4M-22.9%	$58.8M+91.1%	$30.8M-53.9%	$66.8M-6.2%	$71.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$53.0M
Accounts Receivable	$233K+48.4%	$157K-55.3%	$351K	N/A	N/A	$0	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$91.1M-3.0%	$94.0M-5.8%	$99.8M-10.0%	$110.8M-2.5%	$113.7M-9.8%	$126.0M-18.6%	$154.8M-62.1%	$408.8M
Current Liabilities	$19.3M+0.1%	$19.3M-13.9%	$22.4M-27.5%	$30.9M-1.2%	$31.3M-24.0%	$41.2M-36.4%	$64.8M-40.1%	$108.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$110.0M
Total Equity	$26.5M-40.1%	$44.2M+1.2%	$43.7M+32.6%	$33.0M-34.7%	$50.5M+266.1%	$13.8M-42.4%	$23.9M+127.5%	-$87.1M
Retained Earnings	-$992.3M-2.0%	-$972.4M-1.6%	-$957.1M+0.8%	-$965.3M-2.1%	-$945.4M+3.3%	-$978.1M-1.6%	-$962.5M+8.4%	-$1.1B

MCRB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.1M+100.8%	-$148.6M-26.6%	-$117.4M+48.7%	-$228.8M-3521.3%	$6.7M+107.1%	-$93.6M
Capital Expenditures	$252K-33.7%	$380K-95.2%	$8.0M-18.8%	$9.8M+2.7%	$9.6M+1518.6%	$591K
Free Cash Flow	$865K+100.6%	-$149.0M-18.9%	-$125.3M+47.5%	-$238.6M-8191.8%	-$2.9M+96.9%	-$94.2M
Investing Cash Flow	-$42K-100.0%	$142.3M+1244.7%	$10.6M-87.2%	$82.4M+28.6%	$64.1M+140.3%	-$158.9M
Financing Cash Flow	$13.9M+115.4%	-$90.4M-226.0%	$71.7M-44.7%	$129.6M+10901.9%	$1.2M-99.6%	$303.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$16.4M-11.2%	-$14.7M-766.8%	$2.2M+116.6%	-$13.3M-149.4%	$26.9M+169.2%	-$38.9M-12.1%	-$34.7M+12.9%	-$39.8M
Capital Expenditures	$0-100.0%	$29K+262.5%	$8K-95.6%	$181K+432.4%	$34K-62.2%	$90K-30.2%	$129K+30.3%	$99K
Free Cash Flow	-$16.4M-11.0%	-$14.7M-770.6%	$2.2M+116.3%	-$13.5M-150.1%	$26.9M+169.0%	-$39.0M-12.0%	-$34.8M+12.8%	-$39.9M
Investing Cash Flow	$0-100.0%	$181K+2362.5%	-$8K+95.6%	-$181K-432.4%	-$34K+62.2%	-$90K-100.1%	$141.1M+10740.5%	$1.3M
Financing Cash Flow	$428K-96.6%	$12.7M+20649.2%	$61K	$0-100.0%	$1.2M-32.1%	$1.7M+101.6%	-$110.9M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MCRB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-11910.1%	N/A	N/A	-2524.1%-2479.6pp	-44.5%+220.8pp	-265.3%
Net Margin	721.9%	N/A	N/A	-3509.5%-3464.3pp	-45.3%+223.1pp	-268.3%
Return on Equity	12.9%+11.9pp	1.0%	N/A	-2319.9%-2270.1pp	-49.9%+1.1pp	-51.0%
Return on Assets	4.1%+4.0pp	0.1%+31.8pp	-31.7%+40.0pp	-71.7%-53.2pp	-18.5%+7.5pp	-26.0%
Current Ratio	2.56+1.6	0.94-0.8	1.78-0.5	2.28-1.4	3.69-2.1	5.79
Debt-to-Equity	2.13-7.0	9.14+11.6	-2.45-7.1	4.64+4.5	0.18+0.0	0.14
FCF Margin	109.6%	N/A	N/A	-3347.9%-3345.9pp	-2.0%+281.6pp	-283.6%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-5839.9%	N/A	-6403.7%	N/A	N/A	N/A	N/A	N/A
Net Margin	-5562.3%	N/A	2337.3%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-75.1%	N/A	18.8%+79.0pp	-60.3%-125.0pp	64.8%	N/A	371.1%	N/A
Return on Assets	-16.9%	N/A	5.7%+19.5pp	-13.8%-33.7pp	19.9%	N/A	49.7%+59.9pp	-10.2%
Current Ratio	1.65-0.9	2.56+0.3	2.30+0.7	1.57-0.5	2.11+1.2	0.94-0.2	1.12-0.3	1.38
Debt-to-Equity	3.44+1.3	2.13-0.2	2.28-1.1	3.36+1.1	2.25-6.9	9.14+2.7	6.47+7.7	-1.26
FCF Margin	-4569.8%	N/A	626.2%	N/A	N/A	N/A	N/A	N/A

Similar Companies

Alpha Cognition ACOG

$128.2M

Greenwich Lifesciences Inc GLSI

$378.5M

Instil Bio, Inc. TIL

$54.4M

Sangamo Therapeutics Inc SGMO

$55.9M

Coherus CHRS

$232.9M

Frequently Asked Questions

What is Seres Therapeutics Inc's annual revenue?

Seres Therapeutics Inc (MCRB) reported $789K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Seres Therapeutics Inc profitable?

Yes, Seres Therapeutics Inc (MCRB) reported a net income of $5.7M in fiscal year 2025, with a net profit margin of 721.9%.

What is Seres Therapeutics Inc's EBITDA?

Seres Therapeutics Inc (MCRB) had EBITDA of -$89.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Seres Therapeutics Inc's operating margin?

Seres Therapeutics Inc (MCRB) had an operating margin of -11910.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Seres Therapeutics Inc's net profit margin?

Seres Therapeutics Inc (MCRB) had a net profit margin of 721.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Seres Therapeutics Inc's return on equity (ROE)?

Seres Therapeutics Inc (MCRB) has a return on equity of 12.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Seres Therapeutics Inc's free cash flow?

Seres Therapeutics Inc (MCRB) generated $865K in free cash flow during fiscal year 2025. This represents a 100.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Seres Therapeutics Inc's operating cash flow?

Seres Therapeutics Inc (MCRB) generated $1.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Seres Therapeutics Inc's total assets?

Seres Therapeutics Inc (MCRB) had $138.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Seres Therapeutics Inc's capital expenditures?

Seres Therapeutics Inc (MCRB) invested $252K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Seres Therapeutics Inc spend on research and development?

Seres Therapeutics Inc (MCRB) invested $49.1M in research and development during fiscal year 2025.

How many shares does Seres Therapeutics Inc have outstanding?

Seres Therapeutics Inc (MCRB) had 10M shares outstanding as of fiscal year 2025.

What is Seres Therapeutics Inc's current ratio?

Seres Therapeutics Inc (MCRB) had a current ratio of 2.56 as of fiscal year 2025, which is generally considered healthy.

What is Seres Therapeutics Inc's debt-to-equity ratio?

Seres Therapeutics Inc (MCRB) had a debt-to-equity ratio of 2.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Seres Therapeutics Inc's return on assets (ROA)?

Seres Therapeutics Inc (MCRB) had a return on assets of 4.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Seres Therapeutics Inc's Piotroski F-Score?

Seres Therapeutics Inc (MCRB) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Seres Therapeutics Inc's earnings high quality?

Seres Therapeutics Inc (MCRB) has an earnings quality ratio of 0.20x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Seres Therapeutics Inc?

Seres Therapeutics Inc (MCRB) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.